Dr Erin Harvey
|
Registries and Research Coordinator, The University of Newcastle, Australia
Dr Erin Harvey is a biomedical scientist with more than a decade’s experience in complex airways disease registries through The University of Newcastle and John Hunter Hospital, Newcastle, Australia.
Erin has expertise in the setup and management of national and international clinical registries, including the Australian Mepolizumab Registries for both Chronic Rhinosinusitis with Nasal Polyps and Severe Asthma, and the Australasian Severe Asthma Registry. |
|
The Australian Mepolizumab Registry for CRSwNP
Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a high burden disease. Mepolizumab is a targeted anti-Interleukin-5 biologic treatment for severe eosinophilic CRSwNP which reduces symptoms, requirement for surgery and systemic corticosteroid use in randomised controlled trials (RCTs). Clinical registries facilitate the reporting of real-world treatment outcomes in a more generalisable patient population, beyond the narrow eligibility criteria of RCTs.
The Australian Mepolizumab Registry for CRSwNP (AMR-CRSwNP) is a national post-marketing surveillance registry collecting clinical and patient reported outcomes data from patients receiving mepolizumab therapy for the treatment of severe eosinophilic CRSwNP. The registry provides insight into patient characteristics and reports on the use, effectiveness and safety of mepolizumab treatment for CRSwNP in the clinical practice setting.
This presentation will report interim data from participants (n=174) recruited via specialist clinics (n=13) in Brisbane, Sydney, Newcastle, Melbourne, Adelaide and Perth. Participants were enrolled during August 2023 to May 2025, characterised prior to commencing mepolizumab, and outcomes data collected at 12 months. Data collected included CRSwNP history, surgery details, medication use, endoscopic NP scores, peripheral blood eosinophils, symptoms VAS, Sino-Nasal Outcome Test (SNOT-22) scores, ongoing treatment use and adverse drug-related effects.
The Australian Mepolizumab Registry for CRSwNP (AMR-CRSwNP) is a national post-marketing surveillance registry collecting clinical and patient reported outcomes data from patients receiving mepolizumab therapy for the treatment of severe eosinophilic CRSwNP. The registry provides insight into patient characteristics and reports on the use, effectiveness and safety of mepolizumab treatment for CRSwNP in the clinical practice setting.
This presentation will report interim data from participants (n=174) recruited via specialist clinics (n=13) in Brisbane, Sydney, Newcastle, Melbourne, Adelaide and Perth. Participants were enrolled during August 2023 to May 2025, characterised prior to commencing mepolizumab, and outcomes data collected at 12 months. Data collected included CRSwNP history, surgery details, medication use, endoscopic NP scores, peripheral blood eosinophils, symptoms VAS, Sino-Nasal Outcome Test (SNOT-22) scores, ongoing treatment use and adverse drug-related effects.
